filmov
tv
Ipilimumab/Nivolumab for Favorable-Risk mRCC
Показать описание
A debate on the use of ipilimumab/nivolumab as treatment for patients with favorable-risk metastatic renal cell carcinoma.
OncLive
cancer
oncology
Рекомендации по теме
0:07:03
Ipilimumab/Nivolumab for Favorable-Risk mRCC
0:06:16
Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
0:03:16
Optimizing the Use of Ipilimumab/Nivolumab in mRCC
0:08:26
Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC
0:00:51
Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC
0:05:44
HCRN-GU16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced RCC
0:08:40
Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy
0:01:54
Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC
0:55:12
Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC
0:02:09
Tian Zhang, MD, on the follow up study investigating nivolumab + ipilimumab in 1st line RCC patients
0:07:43
Deferred Therapy for Favorable-Risk mRCC Patients
0:27:47
What is the best front line treatment for metastatic clear cell RCC in 2018?
0:01:54
Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRC
0:01:52
HCRN GU16-260: Nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients with adv...
0:01:35
CheckMate-9ER Shows Efficacy of Nivolumab/Cabozantinib Combo in RCC
0:01:05
Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients
0:10:12
Nivolumab + Ipilimumab + 2 Cycles of Platinum-doublet Chemo vs 4 Cycles Chemo for Stage IV NSCLC
0:05:15
Favorable-Risk RCC: Frontline VEGF TKI/IO Combinations
0:05:03
Oncology Bytes - First Line Treatment Patterns in mRCC – Dr Anupama Vijay | IUCS 2024
0:10:02
Unresectable NSCLC - Does Checkmate 227's Suggestion of an Immunotherapy Combination of Yervoy ...
0:01:52
Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line RCC patients
0:38:09
Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC
0:01:38
Patients in CheckMate 067 Demonstrate Durable Complete Responses
0:09:05
mRCC: When is TKI/I-O Combination Therapy Appropriate?
visit shbcf.ru
0:07:03
0:06:16
0:03:16
0:08:26
0:00:51
0:05:44
0:08:40
0:01:54
0:55:12
0:02:09
0:07:43
0:27:47
0:01:54
0:01:52
0:01:35
0:01:05
0:10:12
0:05:15
0:05:03
0:10:02
0:01:52
0:38:09
0:01:38
0:09:05